Bevacizumab for macular edema in central retinal vein occlusion: A prospective, randomized, double-masked clinical study

Ophthalmology

Volumn 119, Issue 6, 2012, Pages 1184-1189

  Epstein, David L J ^a   Algvere, Peep V ^a   Von Wendt, Gunvor ^a   Seregard, Stefan ^a   Kvanta, Anders ^a  

^a ST ERIK S EYE HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

AGED; ANGIOGENESIS; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; IRIS RUBEOSIS; MAJOR CLINICAL STUDY; MALE; NEOVASCULAR GLAUCOMA; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA FOVEA; RETINA MACULA EDEMA; RETINA TEAR; REVIEW; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84861863227     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2012.01.022     Document Type: Article

References (20)

1. S.S. Hayreh, M.B. Zimmerman, P. Podhajsky Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics Am J Ophthalmol 117 1994 429 441
2. P. Mitchell, W. Smith, A. Chang Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study Arch Ophthalmol 114 1996 1243 1247
3. E.M. Opremcak, R.A. Bruce, M.D. Lomeo Radial optic neurotomy for central retinal vein occlusion: a retrospective pilot study of 11 consecutive cases Retina 21 2001 408 415
4. H.J. Zambarakji, S. Ghazi-Nouri, M. Schadt Vitrectomy and radial optic neurotomy for central retinal vein occlusion: effects on visual acuity and macular anatomy Graefes Arch Clin Exp Ophthalmol 243 2005 397 405
5. A. Glacet-Bernard, D. Kuhn, A.K. Vine Treatment of recent onset central retinal vein occlusion with intravitreal tissue plasminogen activator: a pilot study Br J Ophthalmol 84 2000 609 613
6. M.J. Elman, R.Z. Raden, A. Carrigan Intravitreal injection of tissue plasminogen activator for central retinal vein occlusion Trans Am Ophthalmol Soc 99 2001 219 223
7. M. Furukawa, K. Kumagai, N. Ogino Long-term visual outcomes of vitrectomy for cystoid macular edema due to nonischemic central retinal vein occlusion Eur J Ophthalmol 16 2006 841 846
8. A. Glacet-Bernard, K.N. Mahdavi, G. Coscas Macular grid photocoagulation in persistent macular edema due to central retinal vein occlusion Eur J Ophthalmol 4 1994 166 174
9. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: the Central Vein Occlusion Study Group N report Ophthalmology 102 1995 1434 1444
10. SCORE Study Research Group A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 5 Arch Ophthalmol 127 2009 1101 1114
11. J.A. Haller, F. Bandello, R. Belfort Jr OZURDEX GENEVA Study Group Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion Ophthalmology 117 2010 1134 1146
12. L.P. Aiello, R.L. Avery, P.G. Arrigg Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1994 1480 1487
13. S.R. Boyd, I. Zachary, U. Chakravarthy Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion Arch Ophthalmol 120 2002 1644 1650
14. D.M. Brown, P.A. Campochiaro, R.P. Singh CRUISE Investigators Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study Ophthalmology 117 2010 1124 1133
15. P.V. Algvere, D. Epstein, G. von Wendt Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial Eur J Ophthalmol 21 2011 789 795
16. F. Prager, S. Michels, K. Kriechbaum Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial Br J Ophthalmol 93 2009 452 456
17. M.S. Figueroa, I. Contreras, S. Noval, C. Arruabarrena Results of bevacizumab as the primary treatment for retinal vein occlusions Br J Ophthalmol 94 2010 1052 1056
18. S.J. Bakri, M.R. Snyder, J.M. Reid Pharmacokinetics of intravitreal ranibizumab (Lucentis) Ophthalmology 114 2007 2179 2182
19. T.U. Krohne, N. Eter, F.G. Holz, C.H. Meyer Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans Am J Ophthalmol 146 2008 508 512
20. Lucentis (ranibizumab) [package insert] New South Wales; Novartis Australia 2011 3 http://www.novartis.com.au/PI-PDF/luc.pdf Accessed December 28, 2011